Literature DB >> 17081970

PGC-1alpha, a new therapeutic target in Huntington's disease?

Jetta K McGill1, M Flint Beal.   

Abstract

The coactivator PGC-1alpha is a key regulator of mitochondrial biogenesis and respiration, mediating expression of several transcription factors required for these programs. Three new studies reveal that PGC-1alpha expression is downregulated in patients with Huntington's disease (HD) and in several animal models of this neurodegenerative disorder, implicating PGC-1alpha in HD pathogenesis and providing a connection between impaired energy metabolism and neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17081970     DOI: 10.1016/j.cell.2006.10.023

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  53 in total

Review 1.  Antioxidants in Huntington's disease.

Authors:  Ashu Johri; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2011-11-23

2.  Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.

Authors:  Tyisha Hathorn; Abigail Snyder-Keller; Anne Messer
Journal:  Neurobiol Dis       Date:  2010-08-22       Impact factor: 5.996

3.  In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Bin Tang; Alexandre Kuhn; SoongHo Kim; Daniel H Geschwind; Timothy B Brown; Ruth Luthi-Carter; Michelle E Ehrlich
Journal:  Hum Mol Genet       Date:  2010-12-20       Impact factor: 6.150

Review 4.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke.

Authors:  Rawan Tarawneh; James E Galvin
Journal:  Clin Geriatr Med       Date:  2010-02       Impact factor: 3.076

Review 5.  Huntington's Disease and Mitochondria.

Authors:  Mohammad Jodeiri Farshbaf; Kamran Ghaedi
Journal:  Neurotox Res       Date:  2017-06-21       Impact factor: 3.911

6.  Truncated peroxisome proliferator-activated receptor-γ coactivator 1α splice variant is severely altered in Huntington's disease.

Authors:  Ashu Johri; Anatoly A Starkov; Abhishek Chandra; Thomas Hennessey; Abhijeet Sharma; Sara Orobello; Ferdinando Squitieri; Lichuan Yang; M Flint Beal
Journal:  Neurodegener Dis       Date:  2011-07-15       Impact factor: 2.977

Review 7.  Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Nathanael Hevelone; Steven M Hersch
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

8.  PGC-1α overexpression exacerbates β-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease.

Authors:  Magali Dumont; Cliona Stack; Ceyhan Elipenahli; Shari Jainuddin; Nathalie Launay; Meri Gerges; Natalia Starkova; Anatoly A Starkov; Noel Y Calingasan; Davide Tampellini; Aurora Pujol; M Flint Beal
Journal:  FASEB J       Date:  2014-01-07       Impact factor: 5.191

Review 9.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 10.  Does PGC1α/FNDC5/BDNF Elicit the Beneficial Effects of Exercise on Neurodegenerative Disorders?

Authors:  Mohammad Jodeiri Farshbaf; Kamran Ghaedi; Timothy L Megraw; Jennifer Curtiss; Mahsa Shirani Faradonbeh; Pooneh Vaziri; Mohammad Hossein Nasr-Esfahani
Journal:  Neuromolecular Med       Date:  2015-11-26       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.